Longevity Health (XAGE, Financial) has announced significant business developments, including a merger agreement with 20/20 BioLabs. Finalized on April 11, 2025, this agreement stipulates that 20/20 BioLabs will become a wholly owned subsidiary of XAGE after meeting specified conditions. A related S-4 prospectus was filed with the Securities and Exchange Commission on May 8, 2025.
In terms of financial performance, XAGE reported unaudited Q1 sales of approximately $663,000, marking an 8% increase compared to the previous year. Meanwhile, 20/20 BioLabs reported sales of about $562,000, up 15% from the same period last year.
XAGE has also completed a reverse stock split at a ratio of 1-for-30 on May 12, 2025, with trading at the adjusted price commencing on May 14, 2025.
Both companies are planning new product launches in Q2 2025. XAGE intends to introduce a medicated cleanser targeting physicians' offices and medspas, which will also be marketed to 20/20 BioLabs' primary clientele of firefighters. Conversely, 20/20 BioLabs plans to release a new lab test that evaluates inflammatory biomarkers, addressing issues related to premature aging and various disorders.
Furthermore, 20/20 BioLabs is collaborating with Giant Food to offer their OneTestTM cancer screening at selected stores in Maryland and Virginia, with potential plans for expansion. Meanwhile, XAGE is considering additional financing strategies and expects to announce a primary investment by Q2 2025.
